Navigation Links
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
Date:8/12/2008

elective kinase inhibitor, ENMD-2076. The relationship with JSB-Partners will intensify our partnering activities for ENMD-2076, improving our speed and global outreach," commented Thomas H. Bliss, EntreMed Senior Vice President, Corporate and Business Development. Mr. Bliss continued, "Based on the compound's strong preclinical antitumor activity, favorable safety profile, bioavailability, and multiple mechanisms of action, we believe that ENMD-2076 has significant therapeutic potential in a broad range of tumor types. ENMD-2076 represents an exciting clinical-stage opportunity for the right partner."

About JSB-Partners

JSB-Partners is a global transaction advisory firm with a proven history in creating value for its clients. The partners' broad life science and medical backgrounds also include deep and diverse expertise in financial, commercial, and strategic business transactions at the global level. JSB has extensive and trusted relationships with pharma/biotech clients and shareholders, and a proven partnering process, which allows them to achieve optimal transactions and aligned outcomes for stakeholders. JSB's partners are located in Europe, the United States, and Japan.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... ... and rehabilitation clinics throughout New York and New Jersey, acquired South Bay Sports ... its portfolio of state-of-the-art clinics. At this most recent member of the Professional ...
(Date:6/30/2015)... Simi Valley, California (PRWEB) , ... June 30, ... ... quarter of the year, it has proven its continuing growth as a Master ... , On June 17th, the Simi Valley Chamber of Commerce Ambassadors headed by ...
(Date:6/30/2015)... ... , ... America is in a health crisis. Today, 4 out of 5 ... Why? , The answer is simple and is at the core of every disease ... treated over one million patients and, for the first time ever, gives readers and ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Ticket Down is a reliable source for last ... This legendary band has been packing stadiums across North America in conjunction with their 2015 ... they have the energy of a band in their twenties. Some of the most ...
(Date:6/30/2015)... ... June 30, 2015 , ... Earlier ... Introduction to Hyperbaric Medicine Course. Clinicians from WCA partnering hospitals across the country, ... , Wound care and hyperbaric medicine education and training is something that ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Acquires Copiague’s South Bay Sports & Physical Therapy, P.C. 2Health News:1Heart Caregiver Services® Simi Valley Grand Opening 2Health News:1Heart Caregiver Services® Simi Valley Grand Opening 3Health News:1Heart Caregiver Services® Simi Valley Grand Opening 4Health News:12 Easy-To-Follow Steps to Transform Body, Mind and Spirit 2Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Wound Care Advantage Hosts Its First UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3
... University of Pennsylvania,s Abramson Cancer Center have discovered a ... immune system to destroy the cancer,s scaffolding. The strategy ... advanced pancreatic cancer, several of whose tumors shrank substantially. ... way in which they uncovered them -- could lead ...
... , THURSDAY, March 24 (HealthDay News) -- ... significantly shrink pancreatic tumors by targeting the tissue surrounding ... relies on an experimental antibody that sparks the patient,s ... holds tumors together. Although testing has so far ...
... health, but 24.6% of these are not based on any ... Unit at Baza Hospital (Granada), published in the journal BMC ... in primary and secondary school text books in order to ... we classified them into three categories messages with a ...
... Unit in Southampton, UK, have presented a new study ... addition to clinical risk factors (CRFs) and bone mineral ... fracture prediction models. The research findings were presented today ... Valencia, Spain. Using results from the Hertfordshire Cohort ...
... - is just as beneficial as real acupuncture for ... a study from Karolinska Institutet and Linkping University in ... for nausea, felt significant more nausea than patients in ... not to come from the traditional acupuncture method, but ...
... Helena Johansson, Research fellow at the Centre for Bone ... Dr. Maria-Belen Zanchetta, Research fellow at the Instituto de ... the winners of the 2011 ESCEO-AMGEN Fellowship. ... Aspects of Osteoporosis and Osteoarthritis (ESCEO) with support from ...
Cached Medicine News:Health News:Penn researchers uncover novel immune therapy for pancreatic cancer 2Health News:Penn researchers uncover novel immune therapy for pancreatic cancer 3Health News:Novel Treatment for Pancreatic Cancer Under Study 2Health News:Novel Treatment for Pancreatic Cancer Under Study 3Health News:Around 25 percent of health messages in Spanish text books are not based on scientific evidence 2Health News:Acupuncture is equally effective with simulated needles 2
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: